Trial Profile
Prospective, randomized, open-label, clinical trial comparing the effects of ariskiren and amlodipine on blood pressure, endothelial function and makers for obesity/oxidative stress/chronic kidney diseases
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 May 2016
Price :
$35
*
At a glance
- Drugs Aliskiren (Primary) ; Amlodipine (Primary)
- Indications Essential hypertension
- Focus Pharmacodynamics; Therapeutic Use
- 10 Jun 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
- 01 Jun 2011 New trial record